Soterix provides clinicians and patients with the most safe, effective, and user friendly neuromodulation technology.
The most advanced biomedical research and technology at the push of a button. Soterix tDCS devices feature patented stimulation technologies and unparalleled precision.
Individually designed therapies with the power to transform lives. Soterix Solutions enables individualized therapy design for a highly versatile and adaptable tDCS treatment.
The Soterix Clinical Trials stimulator is the most advanced and customizable system for true double-blind control trials.
The Soterix 1×1 Limited Total Energy device is especially designed for stimulation on susceptible subjects.
Introducing the EASYKit – everything you need for a complete tDCS session in a box.
Individual accessories and pre-packaged kits for tDCS clinical trials, including the EASYpad™ sponge electrodes with conductive rubber insets, elastic fastener, EASYStrap and more.
Our exclusive "X configuration" overcomes limitations of conventional tDCS. Soterix HD-tDCS can "penetrate deeper into the brain in more focused areas", reports Nature News.
Physicians at Harvard Medical School demonstrate the application of tDCS for clinical trial on patients using a Soterix 1x1 device in this Journal of Visualized Experiments video.
Soterix EASY-Kits include everything you need for a complete tDCS session in a compact container. Compatible with all Soterix 1x1 Stimulators and Accessories and includes Soterix EASY-Pads.
The CT-tDCS platform is the most sophisticated system for clinical trials with tDCS and the only system to provide true double-blind control and online subject monitoring.
HD-tDCS clinical trial underway for fibromyalgia at Harvard Medical School and Spaulding Rehabilitation Hospital, Boston.
NIH grants Soterix a Phase-1 STTR grant to develop HD-tDCS for stroke rehabilitation. The first technology capable of delivering therapeutic direct current to target brain regions involved in functional recovery.
For the most comprehensive tDCS trial to-date, researchers selected the most advanced tDCS device and the only system optimized for clinical trials – The Soterix Medical 1x1-CT.
Epilepsy Foundation awards a New Therapy Grant for a clinical trial of High-Definition tDCS in pediatric epilepsy. Dr. Alexander Rotenberg will lead a team of clinical investigators including at BCH and Harvard Medical School.
NIH grants Burke Medical Research Institute $3m to conduct the most controlled trial of tDCS for stroke rehabilitation to date. The Soterix Medical 1x1 platform is the most advanced and the industry standard for tDCS clinical trials for rehabilitation.
Soterix Medical Inc. receives FDA Clinical Trial IDE for High-Definition tDCS (HD-tDCS) to improve IQ in pediatric Down syndrome. HD-tDCS is the only non-invasive, brain targeted, and low-intensity technology designed to promote neuroplasticity.
Dr. Bernadette Gillick's Pediatric Rehabilitation Laboratory is supported by the NIH and University of Minnesota Clinical and Translational Science Institute to investigate the use of a form of tDCS for interventions in rehabilitation for children. Subject specific analysis with Soterix Medical Neurotargeting™ will guide current to brain cells in the injured part of the brain.
